FR 901277Alternative Names: WS 7622A
Latest Information Update: 17 Jul 2002
At a glance
- Originator Fujisawa
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Emphysema
Most Recent Events
- 08 Jun 2001 Profile reviewed but no significant changes made
- 23 Jun 1998 Commercial data have been reviewed by Fujisawa
- 20 Feb 1997 New profile